{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:26:31Z","timestamp":1791354391116,"version":"4.3.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T00:00:00Z","timestamp":1561075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T00:00:00Z","timestamp":1561075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005275","name":"Region Hovedstaden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005275","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Genom. Med."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Genomic screening of cancer patients for predisposing variants is traditionally based on age at onset, family history and type of cancer. Whereas the clinical guidelines have proven efficient in identifying families exhibiting classical attributes of hereditary cancer, the frequency of patients with alternative presentations is unclear. We identified and characterized germline variants in 636 patients with advanced solid cancer using whole exome sequencing. Pathogenic and likely pathogenic germline variants among 168 genes associated with hereditary cancer were considered. These variants were identified in 17.8% of the patients and within a wide range of cancer types. In particular, patients with mesothelioma, ovarian cancer, cervical cancer, urothelial cancer, and cancer of unknown primary origin displayed high frequencies of pathogenic variants. Variants were predominantly found in DNA-repair pathways and about half were within genes involved in homologous recombination repair. Twenty-two <jats:italic>BRCA1<\/jats:italic> and <jats:italic>BRCA2<\/jats:italic> germline variants were identified in 12 different cancer types, of which 10 (45%) were not previously identified in these patients based on the current clinical guidelines. Loss of heterozygosity and somatic second hits were identified in several of the affected genes, supporting possible causality for cancer development. A potential treatment target based on the pathogenic germline variant could be suggested in 25 patients (4%). The study demonstrates a high frequency of pathogenic germline variants in the homologous recombination pathway in patients with advanced solid cancers. We infer that genetic screening in this group of patients may reveal high-risk families and identify patients with potential PARP inhibitor sensitive tumors.<\/jats:p>","DOI":"10.1038\/s41525-019-0087-6","type":"journal-article","created":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T10:02:56Z","timestamp":1561111376000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer"],"prefix":"10.1038","volume":"4","author":[{"given":"Birgitte","family":"Bertelsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida Viller","family":"Tuxen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina Westmose","family":"Yde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7959-8767","authenticated-orcid":false,"given":"Migle","family":"Gabrielaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias Husted","family":"Torp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savvas","family":"Kinalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Oestrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristoffer","family":"Rohrberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iben","family":"Spangaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Santoni-Rugiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2882-6798","authenticated-orcid":false,"given":"Karin","family":"Wadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Mau-Sorensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrik","family":"Lassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn Cilius","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,21]]},"reference":[{"key":"87_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","volume":"17","author":"DT Cheng","year":"2015","unstructured":"Cheng, D. T. et al. Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): A hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J. Mol. Diagn. 17, 251\u2013264 (2015).","journal-title":"J. Mol. Diagn."},{"key":"87_CR2","doi-asserted-by":"crossref","unstructured":"Le Tourneau, C. et al. Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. Br. J. Cancer 111, 17\u201324 (2014).","DOI":"10.1038\/bjc.2014.211"},{"key":"87_CR3","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","volume":"7","author":"C Massard","year":"2017","unstructured":"Massard, C. et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 Trial. Cancer Discov. 7, 586\u2013595 (2017).","journal-title":"Cancer Discov."},{"key":"87_CR4","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-12-1627","volume":"18","author":"AM Tsimberidou","year":"2012","unstructured":"Tsimberidou, A. M. et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin. Cancer Res. 18, 6373\u20136383 (2012).","journal-title":"Clin. Cancer Res."},{"key":"87_CR5","doi-asserted-by":"crossref","unstructured":"Tuxen, I. V. et al. Copenhagen Prospective Personalized Oncology (CoPPO) \u2013 Clinical utility of using molecular profiling to select patients to phase 1 trials. Clin. Cancer Res. 25, 1239\u20131247 (2019).","DOI":"10.1158\/1078-0432.CCR-18-1780"},{"key":"87_CR6","doi-asserted-by":"crossref","unstructured":"Green, R. C. et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet. Med. 15, 565\u2013574 (2013).","DOI":"10.1038\/gim.2013.73"},{"key":"87_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/gim.2016.190","volume":"19","author":"SS Kalia","year":"2017","unstructured":"Kalia, S. S. et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SFv2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet. Med. 19, 249\u2013255 (2017).","journal-title":"Genet. Med."},{"key":"87_CR8","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jama.2017.11137","volume":"318","author":"D Mandelker","year":"2017","unstructured":"Mandelker, D. et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. Jama 318, 825\u2013835 (2017).","journal-title":"Jama"},{"key":"87_CR9","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/annonc\/mdw018","volume":"27","author":"F Meric-Bernstam","year":"2016","unstructured":"Meric-Bernstam, F. et al. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann. Oncol. 27, 795\u2013800 (2016).","journal-title":"Ann. Oncol."},{"key":"87_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1001\/jamaoncol.2015.5208","volume":"2","author":"KA Schrader","year":"2016","unstructured":"Schrader, K. A. et al. Germline variants in targeted tumor sequencing using matched normal DNA. JAMA Oncol. 2, 104\u2013111 (2016).","journal-title":"JAMA Oncol."},{"key":"87_CR11","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1158\/1078-0432.CCR-16-0015","volume":"22","author":"BA Seifert","year":"2016","unstructured":"Seifert, B. A. et al. Germline analysis from tumor-germline sequencing dyads to identify clinically actionable secondary findings. Clin. Cancer Res. 22, 4087\u20134094 (2016).","journal-title":"Clin. Cancer Res."},{"issue":"Suppl 8","key":"87_CR12","doi-asserted-by":"publisher","first-page":"viii83","DOI":"10.1093\/annonc\/mdt313","volume":"24","author":"HT Lynch","year":"2013","unstructured":"Lynch, H. T., Snyder, C. & Casey, M. J. Hereditary ovarian and breast cancer: what have we learned? Ann. Oncol. 24(Suppl 8), viii83\u2013viii95 (2013).","journal-title":"Ann. Oncol."},{"key":"87_CR13","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker, K. B. et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. Jama 317, 2402\u20132416 (2017).","journal-title":"Jama"},{"key":"87_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13053-015-0038-x","volume":"13","author":"H Cavanagh","year":"2015","unstructured":"Cavanagh, H. & Rogers, K. M. The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers. Hered. Cancer Clin. Pract. 13, 16 (2015).","journal-title":"Hered. Cancer Clin. Pract."},{"key":"87_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1001\/jama.296.2.185","volume":"296","author":"A Finch","year":"2006","unstructured":"Finch, A. et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. Jama 296, 185\u2013192 (2006).","journal-title":"Jama"},{"key":"87_CR16","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.1200\/JCO.2003.04.131","volume":"21","author":"DA Levine","year":"2003","unstructured":"Levine, D. A. et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J. Clin. Oncol. 21, 4222\u20134227 (2003).","journal-title":"J. Clin. Oncol."},{"key":"87_CR17","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1093\/jnci\/djm203","volume":"99","author":"YC Tai","year":"2007","unstructured":"Tai, Y. C., Domchek, S., Parmigiani, G. & Chen, S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J. Natl. Cancer Inst. 99, 1811\u20131814 (2007).","journal-title":"J. Natl. Cancer Inst."},{"key":"87_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/sj.bjc.6603535","volume":"96","author":"E Levy-Lahad","year":"2007","unstructured":"Levy-Lahad, E. & Friedman, E. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br. J. Cancer 96, 11\u201315 (2007).","journal-title":"Br. J. Cancer"},{"key":"87_CR19","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard, C. C. et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. New Engl. J. Med. 375, 443\u2013453 (2016).","journal-title":"New Engl. J. Med."},{"key":"87_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/(SICI)1098-1004(1997)10:2<89::AID-HUMU1>3.0.CO;2-H","volume":"10","author":"N Papadopoulos","year":"1997","unstructured":"Papadopoulos, N. & Lindblom, A. Molecular basis of HNPCC: mutations of MMR genes. Hum. Mutat. 10, 89\u201399 (1997).","journal-title":"Hum. Mutat."},{"key":"87_CR21","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.2741\/1605","volume":"10","author":"AS Jaiswal","year":"2005","unstructured":"Jaiswal, A. S., Balusu, R. & Narayan, S. Involvement of adenomatous polyposis coli in colorectal tumorigenesis. Front. Biosci. 10, 1118\u20131134 (2005).","journal-title":"Front. Biosci."},{"key":"87_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2014.10.008","volume":"41","author":"P Economopoulou","year":"2015","unstructured":"Economopoulou, P., Dimitriadis, G. & Psyrri, A. Beyond BRCA: new hereditary breast cancer susceptibility genes. Cancer Treat. Rev. 41, 1\u20138 (2015).","journal-title":"Cancer Treat. Rev."},{"key":"87_CR23","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jamaoncol.2016.5592","volume":"3","author":"G Neidhardt","year":"2017","unstructured":"Neidhardt, G. et al. Association between loss-of-function mutations within the FANCM gene and early-onset familial breast cancer. JAMA Oncol. 3, 1245\u20131248 (2017).","journal-title":"JAMA Oncol."},{"key":"87_CR24","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa1400382","volume":"371","author":"AC Antoniou","year":"2014","unstructured":"Antoniou, A. C. et al. Breast-cancer risk in families with mutations in PALB2. New Engl. J. Med. 371, 497\u2013506 (2014).","journal-title":"New Engl. J. Med."},{"key":"87_CR25","doi-asserted-by":"publisher","first-page":"5906","DOI":"10.1038\/sj.onc.1209873","volume":"25","author":"M Ahmed","year":"2006","unstructured":"Ahmed, M. & Rahman, N. ATM and breast cancer susceptibility. Oncogene 25, 5906\u20135911 (2006).","journal-title":"Oncogene"},{"key":"87_CR26","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","volume":"15","author":"M Choi","year":"2016","unstructured":"Choi, M., Kipps, T. & Kurzrock, R. ATM mutations in cancer: therapeutic implications. Mol. cancer Ther. 15, 1781\u20131791 (2016).","journal-title":"Mol. cancer Ther."},{"key":"87_CR27","doi-asserted-by":"publisher","first-page":"R73","DOI":"10.1186\/bcr2919","volume":"13","author":"DE Goldgar","year":"2011","unstructured":"Goldgar, D. E. et al. Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Res. 13, R73 (2011).","journal-title":"Breast Cancer Res."},{"key":"87_CR28","doi-asserted-by":"publisher","first-page":"R495","DOI":"10.1186\/bcr1037","volume":"7","author":"K Heikkinen","year":"2005","unstructured":"Heikkinen, K., Mansikka, V., Karppinen, S. M., Rapakko, K. & Winqvist, R. Mutation analysis of the ATR gene in breast and ovarian cancer families. Breast Cancer Res. 7, R495\u2013R501 (2005).","journal-title":"Breast Cancer Res."},{"key":"87_CR29","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nrc.2016.72","volume":"16","author":"FC Nielsen","year":"2016","unstructured":"Nielsen, F. C., van Overeem Hansen, T. & Sorensen, C. S. Hereditary breast and ovarian cancer: new genes in confined pathways. Nat. Rev. Cancer 16, 599\u2013612 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"87_CR30","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/nrm1493","volume":"5","author":"J Bartek","year":"2004","unstructured":"Bartek, J., Lukas, C. & Lukas, J. Checking on DNA damage in S phase. Nat. Rev. Mol. Cell Biol. 5, 792\u2013804 (2004).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"87_CR31","doi-asserted-by":"publisher","first-page":"26395","DOI":"10.1074\/jbc.R115.660142","volume":"290","author":"R Fishel","year":"2015","unstructured":"Fishel, R. Mismatch repair. J. Biol. Chem. 290, 26395\u201326403 (2015).","journal-title":"J. Biol. Chem."},{"key":"87_CR32","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","volume":"20","author":"KP Pennington","year":"2014","unstructured":"Pennington, K. P. et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin. Cancer Res. 20, 764\u2013775 (2014).","journal-title":"Clin. Cancer Res."},{"key":"87_CR33","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1146\/annurev-med-050913-022545","volume":"66","author":"CJ Lord","year":"2015","unstructured":"Lord, C. J., Tutt, A. N. & Ashworth, A. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu. Rev. Med. 66, 455\u2013470 (2015).","journal-title":"Annu. Rev. Med."},{"key":"87_CR34","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ctrv.2018.04.010","volume":"67","author":"M Papadimitriou","year":"2018","unstructured":"Papadimitriou, M., Mountzios, G. & Papadimitriou, C. A. The role of PARP inhibition in triple-negative breast cancer: unraveling the wide spectrum of synthetic lethality. Cancer Treat. Rev. 67, 34\u201344 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"87_CR35","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo, J. et al. DNA-repair defects and olaparib in metastatic prostate cancer. New Engl. J. Med. 373, 1697\u20131708 (2015).","journal-title":"New Engl. J. Med."},{"key":"87_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ctrv.2016.10.005","volume":"51","author":"F Gelsomino","year":"2016","unstructured":"Gelsomino, F., Barbolini, M., Spallanzani, A., Pugliese, G. & Cascinu, S. The evolving role of microsatellite instability in colorectal cancer: a review. Cancer Treat. Rev. 51, 19\u201326 (2016).","journal-title":"Cancer Treat. Rev."},{"key":"87_CR37","first-page":"341","volume":"21","author":"A Sehdev","year":"2016","unstructured":"Sehdev, A., Cramer, H. M., Ibrahim, A. A., Younger, A. E. & O\u2019Neil, B. H. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature. Discov. Med. 21, 341\u2013347 (2016).","journal-title":"Discov. Med."},{"key":"87_CR38","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1086\/375121","volume":"72","author":"H Meijers-Heijboer","year":"2003","unstructured":"Meijers-Heijboer, H. et al. The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am. J. Hum. Genet. 72, 1308\u20131314 (2003).","journal-title":"Am. J. Hum. Genet."},{"key":"87_CR39","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"87_CR40","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013424 (2015).","journal-title":"Genet. Med."},{"key":"87_CR41","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.3892\/ol.2015.3715","volume":"10","author":"EM Kaluzna","year":"2015","unstructured":"Kaluzna, E. M. et al. Heterozygous p.I171V mutation of the NBN gene as a risk factor for lung cancer development. Oncol. Lett. 10, 3300\u20133304 (2015).","journal-title":"Oncol. Lett."},{"key":"87_CR42","doi-asserted-by":"publisher","first-page":"430","DOI":"10.4161\/cbt.10.5.12763","volume":"10","author":"SG Chun","year":"2010","unstructured":"Chun, S. G. & Yee, N. S. Werner syndrome as a hereditary risk factor for exocrine pancreatic cancer: potential role of WRN in pancreatic tumorigenesis and patient-tailored therapy. Cancer Biol. Ther. 10, 430\u2013437 (2010).","journal-title":"Cancer Biol. Ther."},{"key":"87_CR43","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1073\/pnas.68.4.820","volume":"68","author":"AG Knudson Jr.","year":"1971","unstructured":"Knudson, A. G. Jr. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA 68, 820\u2013823 (1971).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"87_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/srep14060","volume":"5","author":"RM de Voer","year":"2015","unstructured":"de Voer, R. M. et al. Deleterious germline BLM mutations and the risk for early-onset colorectal cancer. Sci. Rep. 5, 14060 (2015).","journal-title":"Sci. Rep."},{"key":"87_CR45","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/humu.22333","volume":"34","author":"CG Smith","year":"2013","unstructured":"Smith, C. G. et al. Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancer. Hum. Mutat. 34, 1026\u20131034 (2013).","journal-title":"Hum. Mutat."},{"key":"87_CR46","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1200\/JCO.2010.34.2980","volume":"29","author":"B Norquist","year":"2011","unstructured":"Norquist, B. et al. Secondary somatic mutations restoring BRCA1\/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol. 29, 3008\u20133015 (2011).","journal-title":"J. Clin. Oncol."},{"key":"87_CR47","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1158\/0008-5472.CAN-08-0088","volume":"68","author":"EM Swisher","year":"2008","unstructured":"Swisher, E. M. et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 68, 2581\u20132586 (2008).","journal-title":"Cancer Res."},{"key":"87_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-017-0011-6","volume":"3","author":"DJ McGrail","year":"2017","unstructured":"McGrail, D. J. et al. Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm. NPJ Syst. Biol. Appl. 3, 8 (2017).","journal-title":"NPJ Syst. Biol. Appl."},{"key":"87_CR49","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cell.2018.03.039","volume":"173","author":"KL Huang","year":"2018","unstructured":"Huang, K. L. et al. Pathogenic germline variants in 10,389 adult cancers. Cell 173, 355\u2013370.e314 (2018).","journal-title":"Cell"},{"key":"87_CR50","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","volume":"2","author":"BM Norquist","year":"2016","unstructured":"Norquist, B. M. et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2, 482\u2013490 (2016).","journal-title":"JAMA Oncol."},{"key":"87_CR51","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","volume":"36","author":"V Panou","year":"2018","unstructured":"Panou, V. et al. Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J. Clin. Oncol. 36, 2863\u20132871 (2018).","journal-title":"J. Clin. Oncol."},{"key":"87_CR52","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1053\/j.gastro.2017.11.004","volume":"154","author":"EM Stoffel","year":"2018","unstructured":"Stoffel, E. M. et al. Germline genetic features of young individuals with colorectal cancer. Gastroenterology 154, 897\u2013905.e891 (2018).","journal-title":"Gastroenterology"},{"key":"87_CR53","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1200\/JCO.2016.71.0012","volume":"35","author":"MB Yurgelun","year":"2017","unstructured":"Yurgelun, M. B. et al. Cancer susceptibility gene mutations in individuals with colorectal cancer. J. Clin. Oncol. 35, 1086\u20131095 (2017).","journal-title":"J. Clin. Oncol."},{"key":"87_CR54","doi-asserted-by":"publisher","first-page":"270","DOI":"10.21037\/tlcr.2017.05.03","volume":"6","author":"M Cheung","year":"2017","unstructured":"Cheung, M. & Testa, J. R. BAP1, a tumor suppressor gene driving malignant mesothelioma. Transl. Lung Cancer Res. 6, 270\u2013278 (2017).","journal-title":"Transl. Lung Cancer Res."},{"key":"87_CR55","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.canlet.2017.06.028","volume":"405","author":"M Betti","year":"2017","unstructured":"Betti, M. et al. Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma. Cancer Lett. 405, 38\u201345 (2017).","journal-title":"Cancer Lett."},{"key":"87_CR56","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jamaoncol.2016.5194","volume":"3","author":"R Pearlman","year":"2017","unstructured":"Pearlman, R. et al. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncol. 3, 464\u2013471 (2017).","journal-title":"JAMA Oncol."},{"key":"87_CR57","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1136\/jmedgenet-2011-100082","volume":"48","author":"AK Win","year":"2011","unstructured":"Win, A. K. et al. Determining the frequency of de novo germline mutations in DNA mismatch repair genes. J. Med. Genet. 48, 530\u2013534 (2011).","journal-title":"J. Med. Genet."},{"key":"87_CR58","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nm.4292","volume":"23","author":"H Davies","year":"2017","unstructured":"Davies, H. et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat. Med 23, 517\u2013525 (2017).","journal-title":"Nat. Med"},{"key":"87_CR59","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-018-0461-z","volume":"562","author":"GM Findlay","year":"2018","unstructured":"Findlay, G. M. et al. Accurate classification of BRCA1 variants with saturation genome editing. Nature 562, 217\u2013222 (2018).","journal-title":"Nature"},{"key":"87_CR60","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/apm.12293","volume":"122","author":"IV Tuxen","year":"2014","unstructured":"Tuxen, I. V. et al. Personalized oncology: genomic screening in phase 1. Acta Pathol., Microbiol., Immunol. Scand. 122, 723\u2013733 (2014).","journal-title":"Acta Pathol., Microbiol., Immunol. Scand."},{"key":"87_CR61","first-page":"1","volume":"00","author":"H Li","year":"2013","unstructured":"Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Oxf. Univ. Press 00, 1\u20133 (2013).","journal-title":"Oxf. Univ. Press"},{"key":"87_CR62","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1093\/bioinformatics\/btx699","volume":"34","author":"BS Pedersen","year":"2018","unstructured":"Pedersen, B. S. & Quinlan, A. R. Mosdepth: quick coverage calculation for genomes and exomes. Bioinformatics. 34, 867\u2013868 (2018).","journal-title":"Bioinformatics."},{"key":"87_CR63","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297\u20131303 (2010).","journal-title":"Genome Res."},{"key":"87_CR64","doi-asserted-by":"crossref","unstructured":"Poplin, R. et al. Scaling accurate genetic variant discovery to tens of thousands of samples. bioRxiv 201178 (2017).","DOI":"10.1101\/201178"},{"key":"87_CR65","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1089\/1066527041410418","volume":"11","author":"G Yeo","year":"2004","unstructured":"Yeo, G. & Burge, C. B. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J. Comput. Biol. 11, 377\u2013394 (2004).","journal-title":"J. Comput. Biol."},{"key":"87_CR66","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/jmg.2005.033878","volume":"43","author":"SV Tavtigian","year":"2006","unstructured":"Tavtigian, S. V. et al. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J. Med. Genet. 43, 295\u2013305 (2006).","journal-title":"J. Med. Genet."},{"key":"87_CR67","first-page":"151","volume-title":"BMC Cancer","author":"J Vikesa","year":"2015","unstructured":"Vikesa, J. et al. Cancers of unknown primary origin (CUP) are characterized by chromosomal instability (CIN) compared to metastasis of know origin. BMC Cancer 15, 151 (2015)."},{"key":"87_CR68","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1677\/ERC-09-0288","volume":"17","author":"R Borup","year":"2010","unstructured":"Borup, R. et al. Molecular signatures of thyroid follicular neoplasia. Endocr. Relat. Cancer 17, 691\u2013708 (2010).","journal-title":"Endocr. Relat. Cancer"}],"container-title":["npj Genomic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41525-019-0087-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41525-019-0087-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41525-019-0087-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T02:38:41Z","timestamp":1671244721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41525-019-0087-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,21]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["87"],"URL":"https:\/\/doi.org\/10.1038\/s41525-019-0087-6","relation":{},"ISSN":["2056-7944"],"issn-type":[{"value":"2056-7944","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,21]]},"assertion":[{"value":"4 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.S-R. has received lecture honoraria from Roche, Pfizer, Novartis, and Boehringer Ingelheim. M.M-S. has received lecture honoraria and support to participate in scientific conference from Roche. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}